Phase 2 study of a Rift Valley fever vaccine for safety
Part of Digestive system, Infections clinical trials.
This study tests how safe a Rift Valley fever (RVF) vaccine is and how strongly it triggers the body’s immune response. You may be eligible if you are at risk of RVF exposure and your blood test shows you don’t already have strong protection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 65 years old when you sign consent
- Your RVF blood test must show low protection: PRNT80 under 1:10 for the main series, or under 1:40 for booster shots
- If you can become pregnant, you must have a urine pregnancy test the same day as each vaccine and agree not to get pregnant for 3 months after the last dose
- You must be at risk for RVF exposure and have submitted a request for the study vaccine through the IND process
- You must complete required screening and follow-up visits, including regular safety check-ins for at least 28 days after each dose
- You must agree to delay blood donation for 1 year after the vaccine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether a VEE (Venezuelan equine encephalitis) booster vaccine is safe and helps your immune system respond in adults. It is for people previously vaccinated with VEE TC-83 who currently have low immune protection.
This study tests a new vaccine called V4020 designed to protect against Venezuelan equine encephalitis (VEE), a virus spread by mosquitoes. The vaccine is given to healthy adults to see if it is safe and creates a good immune response.
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
This trial tests a new rabies vaccine to see how well it works and if it is safe for people who have not been exposed to rabies. It may be a good option if you want protection before potential exposure.
This trial tests a new RSV vaccine in adults aged 60 and older to see if it is safe and helps the immune system fight RSV. If you are generally healthy or have stable medical conditions without recent infections or vaccines, you may be eligible.
This study tests an experimental RSV vaccine (IN006) in healthy adults to check its safety and how well it triggers an immune response. It may help protect against respiratory syncytial virus (RSV), which can cause serious lung infections.
Hear when a new Rift Valley Fever trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.